Avidity Biosciences, Inc.
RNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,897 | $9,560 | $9,224 | $9,326 |
| % Growth | 14% | 3.6% | -1.1% | – |
| Cost of Goods Sold | $0 | $2,101 | $1,387 | $101,182 |
| Gross Profit | $10,897 | $7,459 | $7,837 | -$91,856 |
| % Margin | 100% | 78% | 85% | -984.9% |
| R&D Expenses | $303,593 | $190,968 | $150,404 | $101,182 |
| G&A Expenses | $86,240 | $54,190 | $37,733 | $26,195 |
| SG&A Expenses | $86,240 | $54,190 | $37,733 | $26,195 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2,101 | -$1,387 | -$101,182 |
| Operating Expenses | $389,833 | $243,057 | $186,750 | $26,195 |
| Operating Income | -$378,936 | -$235,598 | -$178,913 | -$118,051 |
| % Margin | -3,477.4% | -2,464.4% | -1,939.6% | -1,265.8% |
| Other Income/Exp. Net | $56,634 | $23,378 | $4,918 | $42 |
| Pre-Tax Income | -$322,302 | -$212,220 | -$173,995 | -$118,009 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$322,302 | -$212,220 | -$173,995 | -$118,009 |
| % Margin | -2,957.7% | -2,219.9% | -1,886.3% | -1,265.4% |
| EPS | -2.89 | -2.91 | -3.34 | -2.85 |
| % Growth | 0.7% | 12.9% | -17.2% | – |
| EPS Diluted | -2.89 | -2.91 | -3.34 | -2.85 |
| Weighted Avg Shares Out | 111,582 | 73,012 | 52,162 | 41,428 |
| Weighted Avg Shares Out Dil | 111,582 | 73,012 | 52,162 | 41,428 |
| Supplemental Information | – | – | – | – |
| Interest Income | $56,882 | $23,972 | $4,975 | $104 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,776 | $2,101 | $1,387 | $639 |
| EBITDA | -$376,160 | -$233,497 | -$177,526 | -$117,412 |
| % Margin | -3,452% | -2,442.4% | -1,924.6% | -1,259% |